FDA Accepts Supplement Application for IMULDOSA by Accord Biopharma
The FDA has accepted the supplemental application for IMULDOSA (USTEKINUMAB-SRLF) from Accord Biopharma.
Company
Pharmaceutical intelligence for Accord Biopharma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.